Applied Therapeutics Inc. is a biotechnology company focused on developing innovative treatments for patients with serious and chronic diseases, particularly those with unmet medical needs. The company's research emphasizes the discovery and advancement of therapeutics that target underlying disease mechanisms, with a primary focus on conditions such as diabetic complications and other metabolic disorders. Applied Therapeutics aims to leverage its expertise in chemistry and biology to bring effective solutions to the market, enhancing patient outcomes and addressing critical health challenges. Through its dedication to scientific rigor and the development of novel compounds, the company strives to make a meaningful impact in the field of medicine.
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws.
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws.
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) investors concerning the Company’s possible violations of federal securities laws.
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) on behalf of investors concerning the Company’s possible violations of federal securities laws.
NEW YORK - (NewMediaWire) - December 09, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT).
NEW YORK - (NewMediaWire) - December 07, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT).
NEW YORK - (NewMediaWire) - December 06, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT).
NEW YORK - (NewMediaWire) - December 05, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT).
NEW YORK - (NewMediaWire) - December 04, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT).
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.
- NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in Q1 2025
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present at the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024, at 7:15 a.m. PT in Rancho Palos Verdes, California.